120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
EGFR A763V突变脑膜转移性NSCLC对奥希替尼治疗的反应：病例报告和文献综述
Received 29 September 2025
Accepted for publication 17 January 2026
Published 21 January 2026 Volume 2026:19 571033
DOI https://doi.org/10.2147/OTT.S571033
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Nagashree Seetharamu
Yu Xu,1,2 Jie Li1,2
1Hubei Key Laboratory of Tumor Biological Behavior, Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China; 2Hubei Cancer Clinical Study Center, Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China
Correspondence: Jie Li, Email lijiewhu@126.com
Abstract: Here, we report a case of a male patient who was initially diagnosed with stage IV driver gene-negative lung adenocarcinoma and received immune checkpoint inhibitors plus chemotherapy as first-line therapy. The patient progressed to meningeal metastasis and harbored an EGFR exon20 p.A763V mutation. A double dose of Osimertinib was recommended and the patient achieved a PFS of 10 months. This report offers evidence that Osimertinib may serve as a treatment option for patients with EGFR exon20 p.A763V mutation. In addition, dynamic spatiotemporal heterogeneity of lung cancer cells should be considered when treating patients with EGFR-positive NSCLC.
Keywords: case report, lung adenocarcinoma, meningeal metastasis, EGFR exon20 p.A763V mutation, osimertinib
1Hubei Key Laboratory of Tumor Biological Behavior, Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China; 2Hubei Cancer Clinical Study Center, Department of Pulmonary Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China
Correspondence: Jie Li, Email lijiewhu@126.com
Abstract: Here, we report a case of a male patient who was initially diagnosed with stage IV driver gene-negative lung adenocarcinoma and received immune checkpoint inhibitors plus chemotherapy as first-line therapy. The patient progressed to meningeal metastasis and harbored an EGFR exon20 p.A763V mutation. A double dose of Osimertinib was recommended and the patient achieved a PFS of 10 months. This report offers evidence that Osimertinib may serve as a treatment option for patients with EGFR exon20 p.A763V mutation. In addition, dynamic spatiotemporal heterogeneity of lung cancer cells should be considered when treating patients with EGFR-positive NSCLC.
Keywords: case report, lung adenocarcinoma, meningeal metastasis, EGFR exon20 p.A763V mutation, osimertinib